Researchers used artificial intelligence to generate a large library of distinct AAV capsid variants, achieving a 60% viable yield. This approach overcomes the limitation of current vectors and expands the number of diseases treatable with gene therapies.
The study found that SRK-181 inhibits latent TGFβ1 activation with high selectivity and overcomes primary resistance to checkpoint blockade therapy by altering the tumor immune landscape. Preclinical results demonstrated improved preclinical safety profiles compared to conventional inhibitors of TGFβ signaling.
The Organs-on-Chips platform provides human-relevant disease modeling and studies to gain insights related to new drug modalities and disease mechanisms. Researchers can use the platform to assess safety risks and make informed decisions throughout the drug discovery and development process.
The HD-MAP vaccine shows significantly enhanced immune responses compared to standard intramuscular injection, with faster onset kinetics and higher overall immune responses. The patch is stable for up to 12 months at temperatures as high as 40°C, providing potential for easy distribution without refrigeration.
The Duodenum Intestine-Chip, a living product from Emulate, Inc., was shown to accurately recreate key functions of the human duodenum. The chip demonstrated superior functionality compared to organoids alone in terms of global transcriptomic profile and physiological function.
A team of scientists has developed an artificial intelligence approach to engineer improved AAV capsids for gene therapy delivery. The research reveals the existence of a previously unknown protein and demonstrates the potential to transform gene therapy. The study's findings have significant implications for the future of gene therapy.
A team of MIT researchers developed an AI-guided robotic platform to streamline the synthesis of small molecule organic compounds. The platform uses artificial intelligence-driven synthesis planning, flow chemistry, and a robotically controlled experimental platform to minimize human intervention.
Researchers used Blood Vessel-Chip to model and predict thrombosis induced by anti-CD154 monoclonal antibody, demonstrating its potential for safety testing and efficacy assessment. The chip recreated key parameters of thrombosis and provided insights into the mechanisms and biomarkers involved.
Scientists at Cedars-Sinai and Emulate are pioneering a Patient-on-a-Chip program to predict which disease treatments would be most effective for each patient. They leverage Organs-on-Chips technology to create an environment where cells exhibit unprecedented biological function, enabling personalized testing of drug treatments.
Researchers have developed a human intestinal lining that mirrors living tissue when placed inside microengineered Intestine-Chips. This breakthrough enables personalized testing of drug treatments for debilitating gastrointestinal diseases such as Crohn's disease and ulcerative colitis.
Researchers provide foundational understanding of myostatin activation mechanism, shedding light on tolloid enzyme's role in generating active myostatin. The study's findings hold promise for developing novel therapies targeting specific structural states of myostatin.
Tramiprosate acts to inhibit the production of neurotoxic beta amyloid oligomers by enveloping the amyloid peptide to prevent its misfolding. This novel mechanism prevents the self-assembly of misfolded proteins into beta amyloid oligomers, leading to neuronal toxicity and clinical progression in Alzheimer's disease.
The Phase 3 analyses of tramiprosate in patients with Mild to Moderate Alzheimer's disease show a gene-dose effect, with the largest clinical benefit seen in patients who are APOE4/4 homozygotes. These results suggest that tramiprosate could be an effective treatment for patients with this genetic risk factor.
Selecta Biosciences' synthetic vaccine particles have been shown to induce antigen-specific immune tolerance, mitigating the formation of anti-drug antibodies and improving the efficacy and safety profile of biologic drugs. The technology has potential applications in treating rare diseases, allergies, and autoimmune diseases.
Researchers at Concert Pharmaceuticals demonstrated selective deuterium substitution to improve safety, efficacy, tolerability and convenience of paroxetine-based medicines. Deuterated compounds retain potency but exhibit altered metabolic profiles, reducing drug-drug interactions.
A novel deuterium-containing sigma-1 agonist, C-10068, demonstrated anti-seizure and anti-inflammatory effects in a preclinical model of traumatic brain injury (TBI). It affected multiple neurochemical pathways, including sigma-1 receptors, which play a widespread modulatory role in the central nervous system.
ANG4043 shows therapeutic brain concentrations in healthy mice and in mice bearing intracranial HER2+ tumors, increasing median survival time by 78% in a HER2+ intracranial tumor model. This technology has the potential to create brain-penetrant mAbs for treating neurological diseases.
A study published in Blood demonstrated that the C1s antibody prevents the destruction of human red blood cells exposed to patient autoantibodies in cold agglutinin disease. The antibody inhibits Complement deposition on the red blood cell membrane, preventing macrophage engagement and lysis.
Preclinical data published in PNAS shows ATSP-7041 suppresses tumor growth in animal models of multiple human xenograft models, including breast cancer and bone cancer. The peptide efficiently penetrates cell membranes and restores p53 function by inhibiting MDM2 and MDMX.
BIND-014, a targeted docetaxel Accurin candidate, demonstrated encouraging anti-tumor activity and was well-tolerated in 28 heavily-pretreated patients with advanced or metastatic solid tumors. The Phase 1 results established the maximum tolerated dose of 60 mg/m2 and showed signs of stable disease lasting at least four cycles.
The study demonstrates that EBI-005 binds to its target, IL-1R1, 85-fold more tightly than IL-Ra, providing a 100-fold increase in potency in vivo. Additionally, EBI-005 has been shown to be more thermally stable than IL-1Ra, indicating potential for a room temperature-stable product.
A broadly protective, fully human monoclonal antibody targeting a conserved region on the influenza hemagglutinin protein provides 100% protection against all H1N1 and H3N2 strains in mouse models. This antibody approach may be a turning point for seasonal and pandemic influenza prevention and treatment.
BIND-014, a novel Accurin nanoparticle, demonstrates high drug concentration in tumors and promising clinical effects in advanced or metastatic cancers. Preclinical data show up to ten-fold increase in intratumoral drug concentrations with prolonged tumor growth suppression.
BIND Biosciences presents late-breaker clinical data for BIND-014, a targeted docetaxel Accurin, showing anti-tumor activity in six of 17 patients with advanced or metastatic solid tumor cancers. The study demonstrated partial response or stable disease with durable responses of up to six months.
Researchers found that resident memory T cells in the skin, called TREMs, provide a powerful and effective immune response against infection. This new understanding challenges immunological dogma and suggests a more effective path to immunity through delivering vaccines to upper layers of the skin.
The study validated the use of a microchip-based device to deliver teriparatide for osteoporosis treatment, with results comparable to standard injections. The implant showed biocompatibility and was well-tolerated by patients, providing proof-of-concept for long-term device viability.
A phase 3 clinical study found that VIVITROL, a once-monthly opioid-blocking medication, significantly increased opioid-free weeks among patients with opioid dependence. The treatment was well-tolerated, with only mild adverse events reported. The results suggest that VIVITROL is an important new option for treating opioid dependence.
The article discusses the resurgence of covalent drugs, which have made a major positive impact on human health, and highlights the potential of rational covalent drug design to expand their use. Several rationally designed covalent inhibitors are advancing in clinical development, addressing problems of drug-resistance mutations.
Research validates Pentraxin-2/SAP as a novel therapeutic approach for treating lung fibrosis, including IPF. PTX-2/SAP potently inhibits TGF-beta1 driven pathologies without affecting growth factor levels.
Researchers at Avila Therapeutics have developed the first-ever covalent irreversible inhibitors of a viral protease, achieving high selectivity and potency. The newly designed compounds irreversibly bind to molecular domains specific to proteases, offering a promising therapeutic approach for hepatitis C infection.
Researchers at Agios Pharmaceuticals have discovered that the mutated IDH1 gene produces a metabolite called 2-hydroxyglutarate, which contributes to the formation and progression of gliomas. This finding validates cancer metabolism as an approach to identify new ways to treat cancer.
Researchers discovered that Stapled Peptides can potently and directly inhibit the Notch transcription factor complex, preventing cancer cell proliferation and survival. The findings validate the potential of Stapled Peptides to modulate key intracellular biological targets.
ANG1005 demonstrates disease control in over 70% of patients with progressive gliomas and brain metastases, with significant reductions in tumor size observed. The drug successfully crosses the blood-brain barrier without CNS toxicity or immunogenicity.
Resolvyx Pharmaceuticals announced positive Phase 2 clinical study results for RX-10045, a resolvin administered as a topical eye drop for treating patients with chronic dry eye syndrome. The 28-day trial showed dose-dependent improvements in symptoms and signs of dry eye.
Two Agios founders have authored a Science review on cancer metabolism, summarizing the current state of the field and suggesting new targets for therapy. The review highlights key advancements in understanding how cancer cells adapt to use more nutrients than normal cells.
A study published in PNAS identified TRPA1 as playing a key role in allergic asthma and demonstrated that HC-030031 effectively treated the condition in mice. This breakthrough research could represent a new avenue of treatment for asthma.